国際抗老化再生医療学会雑誌 第 6 巻（20−33）2024
By Shinichiro Akiyama, MD, PhD, FACP
Cancer gene; Immunotherapy Expert
Clinical Oncology, McGill University, CANADA
Faculty of Science and Technology, Keio University, JAPAN
Mechanism of Action
Electro Capacitive Cancer Therapy (ECCT) employs low-voltage, medium-frequency electric fields to disrupt mitotic progression by inducing microtubule depolymerization, ultimately triggering apoptosis in cancer cells while sparing normal tissues. By interfering with the electrostatic forces that stabilize spindle formation during cell division, ECCT selectively targets proliferating malignant cells without the systemic toxicity associated with conventional therapies such as chemotherapy and radiotherapy.
Preclinical Evidence
In vitro and in vivo studies have demonstrated ECCT’s efficacy in suppressing tumor growth, with research indicating a 28–39% reduction in cancer cell proliferation and significant tumor shrinkage in murine models. Further investigations have revealed ECCT-mediated downregulation of IL-18 and CCL-2, key inflammatory cytokines implicated in tumor progression, as well as p53-independent p21 pathway activation leading to apoptosis in osteosarcoma cells. These findings highlight ECCT’s potential as a targeted, non-cytotoxic oncologic intervention.
Clinical Evidence
ECCT has shown promising outcomes in multiple malignancies, including glioblastoma multiforme (GBM), breast cancer, lung cancer, and lymphoma, as evidenced by a retrospective analysis of 5,195 patients. A Kaplan-Meier survival analysis in GBM patients revealed a median overall survival (OS) of 28.9 months for ECCT-treated individuals versus 15.6 months for those receiving Temozolomide (TMZ) alone, suggesting superior efficacy with ECCT. Furthermore, ECCT’s safety profile was highly favorable, with no high-grade systemic toxicity reported and only mild, localized discomfort in select cases.
Tumor Response Classification
Electrical Capacitance Volume Tomography (ECVT) has enabled the stratification of tumor responses into five categories, with soft, medium-to-high-grade tumors exhibiting the most favorable responses to ECCT, while highly aggressive phenotypes necessitate extended monitoring due to rapid metastatic potential. These findings suggest that ECCT may be particularly effective in certain tumor subtypes, warranting further investigation into
patient selection criteria.
Future Directions
As a non-invasive, well-tolerated therapeutic modality, ECCT holds significant potential for patients with advanced, refractory, or chemotherapy-intolerant malignancies. Future research will focus on optimizing treatment parameters, investigating synergies with immune checkpoint inhibitors, and conducting large-scale, randomized clinical trials to establish ECCT as a paradigm-shifting oncologic intervention with broad clinical applicability.
If validated through further studies, ECCT could redefine the landscape of cancer treatment by offering a novel, mechanistically distinct alternative to conventional cytotoxic therapies.
